Loading...
At this year's meeting of the American Society of Clinical Oncology (ASCO 2019), held May 31 to June 4 in Chicago, investigators discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were on hand to report highlights of the conference. Here, Robert Dreicer, MD, MS, FACP, FASCO, reviews key presentations on new genitourinary cancer therapies. All meeting abstracts can be viewed in the ASCO meeting library.
Although management options for patients with advanced urothelial cancer have improved following the introduction of checkpoint inhibitors, only a relatively small subset of patients will respond to those agents. Thus, a significant unmet …